Related Experiment Video
Updated: Feb 28, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Long-Term Clinical Outcomes of PCI Versus Medical Therapy in NSTEMI Patients with Prior CABG
Onur Altınkaya1, Selim Aydemir1, Murat Özmen1
1Department of Cardiology, University of Health Sciences, Erzurum City Hospital, 25240 Erzurum, Turkey.
Insights
For patients with prior coronary artery bypass grafting (CABG) experiencing non-ST-segment elevation myocardial infarction (NSTEMI), percutaneous coronary intervention (PCI) showed no long-term benefit over medical therapy. Prognosis depends more on conditions like hypoalbuminemia, chronic kidney disease (CKD), and heart failure (HF).
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiovascular Research
Background:
- Patients with prior coronary artery bypass grafting (CABG) and non-ST-segment elevation myocardial infarction (NSTEMI) are a high-risk subgroup.
- The optimal management strategy (invasive percutaneous coronary intervention [PCI] vs. conservative medical therapy) for these patients remains uncertain.
- Advanced comorbidity burden and complex coronary anatomy contribute to the challenges in managing this population.
Purpose of the Study:
- To compare the long-term outcomes of PCI versus medical therapy in NSTEMI patients with a history of CABG.
- To identify independent predictors of major adverse cardiovascular events (MACE) and all-cause mortality in this specific patient cohort.
- To inform clinical decision-making for complex cardiovascular cases.
Main Methods:
- Retrospective cohort study of 286 NSTEMI patients with prior CABG.
- Comparison of outcomes between patients treated with PCI (n=112) and those receiving medical therapy (n=174).
- Assessment of baseline characteristics, MACE, all-cause mortality using Kaplan-Meier analysis and multivariable Cox regression.
Main Results:
- No significant difference in MACE rates between PCI and medical therapy groups (14.3% vs. 18.9%, p=0.305).
- Similar all-cause mortality rates observed in both groups (9.8% vs. 10.3%, p=0.541).
- Hypoalbuminemia independently predicted MACE and mortality; chronic kidney disease (CKD) and heart failure (HF) were significant determinants of mortality.
Conclusions:
- Percutaneous coronary intervention (PCI) does not offer a long-term survival advantage over medical therapy for NSTEMI patients with prior CABG.
- Patient prognosis is more strongly associated with comorbidities such as hypoalbuminemia, CKD, and HF than with the revascularization strategy.
- Individualized, risk-adapted treatment strategies are crucial for managing this complex, high-risk cardiovascular patient population.
Abstract:
Background and Objectives: Patients with a prior history of coronary artery bypass grafting (CABG) who present with non-ST-segment elevation myocardial infarction (NSTEMI) represent a complex, high-risk subgroup due to advanced comorbidity burden and challenging coronary anatomy. Whether an invasive strategy offers meaningful benefit over conservative management in this population remains unclear. Therefore, this study aimed to compare long-term outcomes of percutaneous coronary intervention (PCI) versus medical therapy in NSTEMI patients with previous CABG and to identify independent predictors of major adverse cardiovascular events (MACE) and all-cause mortality. Materials and Methods: This retrospective cohort study included 286 NSTEMI patients with prior CABG (PCI: 112; medical therapy: 174). Baseline demographic, clinical, laboratory, and angiographic characteristics were assessed. The primary endpoint was MACE, while the secondary endpoint was all-cause mortality. Kaplan-Meier analysis evaluated survival differences, and multivariable Cox regression identified independent predictors. Results: During follow-up, MACE rates were comparable between PCI and medical therapy (14.3% vs. 18.9%; p = 0.305). All-cause mortality was likewise similar (9.8% vs. 10.3%; p = 0.541). Kaplan-Meier analysis showed no survival benefit with PCI (log-rank p = 0.334). Hypoalbuminemia independently predicted both MACE and mortality, while CKD and HF were major determinants of long-term mortality. Conclusions: In NSTEMI patients with prior CABG, no long-term superiority of PCI over medical therapy was observed with respect to MACE or mortality. Prognosis appears more closely linked to hypoalbuminemia, CKD, and HF than to the chosen management strategy. These findings underscore the importance of individualized and risk-adapted clinical decision-making in this complex population.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management
01:30Acute Coronary Syndrome I: Introduction
01:20Angina V: Nursing Management
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations